How Long Does It Take to See Results with GLP-1 Agonists like Mounjaro or Wegovy?

By 
Dr Amit Kumar Singh
 on 
Nov 19, 2024
 • 
5
 min read

Many people embarking on a weight management GLP-1 (Glucagon-like peptide-1) agonists often experience a mix of anticipation and frustration. It’s natural to feel a sense of urgency when it comes to health, especially in a world where immediate results seem to dominate the narrative.

You might be wondering, "Why isn’t the scale moving as quickly as I’d hoped?" or "When will I start to feel the benefits of this medication?" These questions can be disheartening, especially when you’re putting in the effort to make lifestyle changes and stick to your treatment plan. It’s easy to feel like progress is just out of reach, like you're on a treadmill, running hard but not getting anywhere.

However, amid the frustration, there is a glimmer of hope. Understanding the timeline for seeing results with GLP-1 agonists can transform your experience from one of impatience to a journey of patience and self-discovery. While every person’s experience is unique, many find that with the right mindset and realistic expectations, progress is not just possible—it’s achievable. In this article, we’ll delve into what you can typically expect when using GLP-1 agonists, helping to illuminate the path ahead and reminding you that meaningful change often takes time. Let's explore this journey together!

Timeframe for Weight Loss Results with GLP-1 Agonists

GLP-1 receptor agonists, such as Wegovy (semaglutide) and Mounjaro (tirzepatide), are designed to regulate blood sugar and appetite by enhancing insulin release, reducing glucagon, and slowing digestion. By promoting feelings of fullness, these medications support gradual and sustained weight loss, making them effective tools for managing obesity, diabetes, and overall metabolic health.

Weight loss with GLP-1 agonists typically occurs in three distinct phases, each with its own timeframe:

Weight Loss Phases with GLP-1 Agonists:

  1. Initial Phase (Weeks 1–4): Patients often begin to notice weight loss within the first 2 to 4 weeks of treatment. Clinical studies have shown that individuals can experience a weight reduction of approximately 2–4% of their total body weight during this period.
  2. Continued Weight Loss (Months 2–6): With ongoing treatment, weight loss continues at a steady pace. By the 12-week mark, patients may achieve a total weight loss of around 5–10%.
  3. Maintenance Phase (Beyond 6 Months): After six months, weight loss typically plateaus. Sustained use of GLP-1 agonists, combined with lifestyle modifications, helps maintain the achieved weight loss. Long-term studies indicate that patients can maintain a weight loss of approximately 10–15% of their initial body weight after one year of treatment. 

Strategies to Overcome Plateaus

To navigate these plateaus, several strategies can be employed:

  • Adjusting Dosage: Consulting with healthcare providers to potentially adjust the dosage of GLP-1 agonists may enhance their effectiveness.
  • Incorporating Lifestyle Modifications: Engaging in regular physical activity and reassessing dietary habits can help break through plateaus. For instance, increasing protein intake has been shown to reduce hunger and improve satiety, which may aid in overcoming weight loss stalls.

Long-Term Weight Loss

Continued treatment with GLP-1 agonists has been associated with sustained weight loss over time. Clinical trials have shown that individuals who maintain adherence to their medication regimen can achieve significant long-term weight reductions. For example, participants in studies have reported maintaining an average excess weight loss of around 11% over a year following treatment initiation.

Importance of Adherence and Lifestyle Changes: Long-term success in weight management relies heavily on adherence to medication and lifestyle modifications. Maintaining a balanced diet, engaging in regular physical activity, and monitoring caloric intake are essential components for sustaining weight loss achieved through GLP-1 agonist therapy. Research suggests that consistent engagement with healthcare professionals for support can further enhance adherence rates and overall success in maintaining weight loss.

Factors Affecting Weight Loss Results with GLP-1 Agonists

Individual Variation

Individual characteristics such as metabolism, genetics, and baseline weight significantly influence weight loss outcomes when using GLP-1 agonists. For instance:

  • Metabolism: Individuals with a higher metabolic rate may experience faster weight loss compared to those with slower metabolism. A study published in Diabetes Care indicated that metabolic factors could account for variations in weight loss among patients treated with liraglutide, where participants with a higher resting metabolic rate lost more weight over 26 weeks.
  • Genetics: Genetic predispositions can affect how individuals respond to GLP-1 therapy. Research has shown that polymorphisms in the GLP-1 receptor gene may influence the effectiveness of treatment, affecting both appetite regulation and insulin sensitivity.
  • Baseline Weight: Baseline weight also plays a crucial role; individuals with higher initial weights tend to experience greater absolute weight loss. For example, a clinical trial involving semaglutide reported that participants with a baseline body mass index (BMI) over 35 kg/m² lost an average of 15% of their body weight after 68 weeks, while those with lower baseline weights lost less in relative terms.

These factors can impact not only the rate but also the extent of weight loss achieved through GLP-1 agonist therapy.

Which is better? Mounjaro or Wegovy? 

When considering GLP-1 agonists for weight loss, it's natural to wonder how Mounjaro and Wegovy compare in terms of effectiveness. Both medications have shown significant results in clinical trials, but the timeline and extent of weight loss can vary between the two.

To help visualise the expected weight loss at different doses, let's look at this comparative table:

These percentages represent average weight loss from baseline over a 68-72 week period, based on the SURMOUNT-1 trial for Mounjaro and the STEP-1 trial for Wegovy.

As we can see, Mounjaro tends to show higher weight loss percentages across all doses compared to Wegovy. At the highest doses, Mounjaro users experienced an average weight loss of about 22.5% of their initial body weight, while Wegovy users saw an average loss of about 15%.

Lifestyle Factors

Combining GLP-1 agonist therapy with lifestyle modifications is essential for maximising weight loss and improving overall health. Studies suggest that:

  • Dietary Changes: Implementing a balanced diet can enhance the effects of GLP-1 agonists. A randomised trial found that patients who adhered to a low-calorie diet while on liraglutide lost significantly more weight than those who did not modify their diet, averaging an additional 3 kg over six months.
  • Physical Activity: Regular exercise complements the appetite-suppressing effects of GLP-1 agonists. A study on the long term effect of semaglutide demonstrated that individuals who engaged in regular physical activity while on semaglutide experienced greater weight loss (up to 20%) compared to those who did not exercise.

Tips on Improving Weight Loss with GLP-1s 

While GLP-1 medications like Mounjaro and Wegovy are highly effective for weight loss, their impact can be significantly enhanced by making certain lifestyle and behavioural adjustments. Here are some expert-backed tips to optimise your weight loss journey:

1. Follow a Balanced, Nutrient-Dense Diet

  • Focus on whole, unprocessed foods like lean proteins, whole grains, fruits, and vegetables.
  • Limit added sugars, refined carbs, and saturated fats, which can slow down your progress.
  • Incorporate high-fibre foods to promote satiety and improve gut health.

2. Stay Consistent with Medication

  • Take your medication exactly as prescribed by your healthcare provider.
  • Maintain your dosing schedule to ensure optimal blood sugar regulation and appetite control.

3. Hydrate Properly

  • Aim to drink at least 8–10 glasses of water per day
  • Staying hydrated can help reduce hunger cues often mistaken for thirst.

4. Incorporate Regular Physical Activity

  • Combine aerobic exercises (e.g., walking, cycling) with strength training for maximum results.
  • Start with small, achievable goals if you’re new to exercise, and gradually increase intensity.

5. Track Your Progress

  • Keep a journal of your meals, physical activity, and weight changes.
  • Use apps or wearable devices to monitor calorie intake and activity levels.

6. Prioritise Sleep

  • Aim for 7–9 hours of quality sleep per night.
  • Poor sleep disrupts hormones related to hunger and satiety, potentially hindering weight loss.

7. Manage Stress Effectively

  • Practice stress-reducing techniques like mindfulness, meditation, or yoga.
  • Chronic stress can lead to emotional eating and weight gain.

8. Set Realistic Expectations

  • Understand that sustainable weight loss takes time and may not happen at the same pace for everyone.
  • Celebrate small milestones to stay motivated.

9. Work with a Healthcare Professional

  • Regularly check in with your healthcare provider or a registered dietitian.
  • They can help adjust your treatment plan, provide personalised dietary advice, and address any side effects.

10. Build a Support System

  • Engage with friends, family, or support groups who can encourage and motivate you.
  • Share your goals and progress to create accountability.

Conclusion

GLP-1 agonists offer a powerful tool for weight loss and diabetes management, but their success depends on a combination of personalised treatment and healthy lifestyle choices. Individual factors such as genetics, metabolism, and baseline weight influence outcomes, while a balanced diet and regular exercise significantly enhance results. Consulting with a healthcare professional ensures a tailored approach, optimising both safety and effectiveness for long-term success.

Frequently Asked Questions

1. What are GLP-1 agonists, and how do they work for weight loss?
GLP-1 agonists are medications that mimic the hormone GLP-1, which helps regulate appetite and insulin. They can promote weight loss by enhancing feelings of fullness, reducing hunger, and slowing down gastric emptying, which can lead to lower calorie intake.

2. Are GLP-1 agonists safe for women in the UK?
Yes, GLP-1 agonists are generally considered safe for women, but it’s essential to consult with a healthcare professional to discuss any individual health concerns, medical history, or potential side effects.

3. Can I take GLP-1 agonists while pregnant or breastfeeding?
GLP-1 agonists are not recommended during pregnancy. It’s crucial to discuss your options with your healthcare provider.

4. How much weight can I realistically expect to lose while on GLP-1 agonists?
Weight loss can vary widely among individuals, but many people lose between 5% to 10% of their body weight over six months to a year. Factors such as diet, exercise, and individual metabolism play significant roles.

5. Are there any specific dietary recommendations while on GLP-1 agonists?
Focusing on a balanced diet rich in fruits, vegetables, whole grains, and lean proteins is advisable. Staying hydrated and avoiding high-calorie, low-nutrient foods can also help maximise results.

6. Where can I access GLP-1 agonists in the UK?
GLP-1 agonists are available through prescription from SheMed Healthcare. Speak to our specialist and book your blood test for GLP-1 eligibility.

References

Sign up now to get priority access!

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.